References
- Jackson DV, Sethi VS, Spurr CL, et al. Intravenous vincristine infusion: Phase I trial. Cancer 1981; 48: 2559–2564
- Jackson DV, Jr, Paschold EH, Spurr CL, et al. Treatment of advanced non-Hodgkin's lymphoma with vincristine infusion. Cancer 1984; 53: 2601–2606
- Tiber C, Conrad F, Hagemeister R. Continuous vinblastine for previously treated non-Hodgkin's lymphoma. Proc Am Assoc Cancer Res 1980; 21: 162
- Kaplon M, Jackson DV, Spurr CL, et al. VP-16-213 vincristme (VCR) infusion in refractory non-Hodgkin's lymphomas (NHL). Proc Am Soc Clin Oncol. 1985; 4: 202
- Craig J, Jackson D, Powell B, et al. Continuous infusion vincristine (V) as a component of initial chemotherapy for Stage III-IV diffuse histiocytic lymphoma (DHL). Roc Am Assoc Cancer Res 1985; 26: 182
- Yap HY, Blurnenschein GR, Keating MJ, et al. Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer. Cancer Treat Rep 1980; 64: 279–283
- Jackson DV, Jr, Bender RA. The clinical pharmacology of the vinca alkaloids epipodophyllotoxins, and waytansix. Clinical Pharmacologp of Anti-Neoplastic Drugs, HM. Pinedo. Elsevier/North Holland Biomedical Press, New York 1978
- Livingston RB, Carter SK. Single Agents in Cancer Chemotherapy. Plenum Press, New York 1970; 279–377
- Johnson IS, Armtrong JG, Gorman M, et al. The vinca alkaloids: A new class of oncolytic agents. Cancer Res 1963; 23: 1390–1427
- Carbone PP, Bono V, Frei E, III, et al. Clinical studies with vincristine. Blood 1963; 21: 640–647
- Holland JF, Scharlau C, Gailani S, et al. Vincristine treatment of advanced cancer: a cooperative study of 392 cases. Cancer Res 1973; 33: 1258–1264
- Miaskowski C, Vogl S, Kaplan B. Safety of continuous infusion of vinca alkaloids (vindesine and vinblastine) via peripheral vein. Proc Am Assoc Cancer 1984; 25: 364